NCT05148000

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Open-label Study to Assess Aesthetic Improvement Following Treatment With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study to assess aesthetic improvement following treatment with QM1114-DP.

Detailed description

This is an open-label, single-center multi-center study to assess aesthetic improvement in the Glabellar and Lateral Canthal regions following treatment with QM1114-DP.

Conditions

• Glabellar Frown Lines
• Canthal Lines

Interventions

Type	Name	Description
BIOLOGICAL	QM1114-DP	QM1114-DP

Timeline

• Start date: 2023-01-23
• Primary completion: 2023-03-31
• Completion: 2023-06-23
• First posted: 2021-12-07
• Last updated: 2024-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study